Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3433 - Prevalence, risk factors and management of opioid-induced constipation in cancer pain: a nationwide, cross-sectional study in Korea

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Seung Yeon Lee

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

S.Y. Lee1, Y.S. Hong2, K.T. Lee3, S.H. Shin4, M.Y. Choi5, S.J. Sym6, H. Oh7, S.N. Lee8, E. Song9

Author affiliations

  • 1 Medical Department, Mundipharma Korea Ltd, 04637 - Seoul/KR
  • 2 Medical Oncology, The Catholic University of Korea, Seoul St. Mary’s Hospital, 06591 - Seoul/KR
  • 3 Medical Oncology, Soon Chun Hyang University Hospital Cheonan, 31151 - Cheonan/KR
  • 4 Hematology-oncology, Kosin University Gospel Hospital, 49267 - Busan/KR
  • 5 Medical Oncology, Inje University Busan Paik Hospital, 47392 - Busan/KR
  • 6 Medical Oncology, Gachon University Gil Medical Center, 405-760 - Incheon/KR
  • 7 Medical Oncology, GangNeung Asan Hospital, 25440 - hosukoh@hanmail.net/KR
  • 8 Medical Oncology, Ewha Womans University School of Medicine, 07985 - Seoul/KR
  • 9 Medical Oncology, Chonbuk National University Medical School, 561180 - Jeonju/KR
More

Resources

Abstract 3433

Background

As opioid therapy is the mainstay treatment for moderate-to-severe cancer pain, a thorough investigation of opioid-induced constipation (OIC) is important due to high prevalence in cancer pain patients undergoing opioid therapy. This study aimed to investigate the prevalence, risk factors and management of opioid-induced constipation among cancer pain patients in Korea.

Methods

A cross-sectional analysis of cancer patients with pain from 30 teaching hospitals was performed, with data extracted from patient charts and questionnaires. Clinical characteristics, prevalence and management for AEs were assessed.

Results

Among 2,395 patients, the most common opioid-related AE was constipation (29.69%). The impact of overall AEs on patients’ daily activities was the highest for constipation (69.80%, ≥3). Route of opioid administration was not associated with increased opioid-induced constipation. However, OIC occurrence was dependent to opioid dose. Although approximately half of patients used laxatives prophylactically, 18.50% of those patients experienced constipation. In particular, opioid-use duration, use of laxatives, dose and GI surgery history were significantly associated with constipation.

Conclusions

This study evaluated opioid-induced constipation in cancer pain patients in Korea. As evidenced by the negative impact on patients’ daily activities, proper management of OIC is critical as OIC persists although with the use of laxatives. Use of prophylactic laxatives was an important effector as the occurrence of constipation was lower in patients using laxatives prophylactically compared with those using laxatives for constipation treatment. Patients may also benefit from more specific and innovative therapy such as agonist/antagonist combination as stated in EFIC guideline.

Clinical trial identification

Legal entity responsible for the study

Mundipharma Korea Ltd.

Funding

Mundipharma Korea Ltd.

Editorial Acknowledgement

Medical writing and editorial support was provided by Geraldine Toh of Tech Observer Asia Pacific. This support was funded by Mundipharma Korea Ltd.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.